N. prodotti: 0
Totale ordine: € 0,00
Indexed/Abstracted in: BIOSIS Previews, EMBASE, Scopus, Emerging Sources Citation Index
Online ISSN 1827-1812
Valverde S. 1, Canistro R. 2, Gessoni F. 3, Piccione A. 1, Perini C. 1, Gessoni G. 1, 3
1 Service of Laboratory Medicine, Ospedale Madonna della Navicella, Chioggia, Venice, Italy;
2 Service of Hematology and Oncology, Ospedale Madonna della Navicella, Chioggia, Venice, Italy;
3 Transfusional Service, Ospedale Madonna della Navicella, Chioggia Venice, Italy
AIM: The aim of this study was to evaluate the hypothesis that testing for multiple antiphospholipid antibody (aPL) specificities may help to identify the antiphospholipid syndrome (APS) in patients with previous thrombosis.
METHODS:Were evaluated 292 patients with previous veins thrombosis. All patients were tested for lupus anticoagulant (LA), IgG and IgM antibodies to cardiolipin (aCL IgG and IgM CL), anti- prothrombin IgG (aPR IgG), IgG and IgM anti-β2glicoprotein1 (aB2GP1 IgG and IgM), anti annexin V IgG (aANV IgG) and anti- phosphatidylserine / Prothrombin complex IgG (IgG AFS).
RESULTS: Of the 292 patients 84 (29%) were confirmed positive for aPL. Among patients with APS 96% were positive for LA; 21.4% for a CL IgG and 16.7% aCL IgM; 39.2% for aB2GP1 IgG and 14.9 for aB2GP1 IgM; 20.2 for aPR IgG; 20.2 for aANV IgG and 14.2 were positive for aFS IgG. In this patient series 70% presented multiple aPL reactivity.
Discussion. In this series LA has proven the test with higher sensitivity resulting positive in 96 % of patients with APS. In this series research of other aPL increased results specificity. Patterns characterized by multiple reactivity (from two to seven) has been detected.
CONCLUSION: In our series, it was not possible to relate a pattern of reactivity with a peculiar clinical presentation nor with the severity of the disease.